• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

RPE and photoreceptor damage in geographic atrophy patients may be delayed by pegcetacoplan

News
Article

The hypothesis is based on a post hoc analysis of data from 2 phase 3 clinical trials of pegcetacoplan by Dun Jack Fu, PhD, and colleagues.

(Image Credit: AdobeStock/Brian Jackso)

(Image Credit: AdobeStock/Brian Jackso)

A new study found evidence that suggested that pegcetacoplan (Syfovre, Apellis Pharmaceuticals) may delay atrophy of the retinal pigment epithelium (RPE) and photoreceptors in patients with geography atrophy (GA),1 reported Dun Jack Fu, PhD, from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London. He, along with colleagues from the Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, the Netherlands, and Apellis Pharmaceuticals, Waltham, MA, undertook this post hoc analysis of data from 2 phase 3 clinical trials of pegcetacoplan.

Spectral-domain optical coherence tomography (SD-OCT) has been the go-to technology to evaluate GA; however, according to the authors, determining the changes in GA progression, based on the Consensus of Atrophy Meetings (CAM) group, requires manual segmentation of OCT volume scans, which is time consuming, labor intensive, and limited by interrater variability.2-4

The authors suggested that the process can be stream-lined by using automated image segmentation algorithms. They recently developed a deep-learning based platform that uses CAM-defined OCT features to detect and quantify GA and its components.

This post hoc analysis of the OAKS (NCT03525613) and DERBY (NCT03525600) studies included 11,614 SD-OCT volumes from 936 of the 1,258 participants with GA in the 2 parallel 24-month, randomized, double-masked, phase 3 studies, OAKS and DERBY were 24-month, multicenter, randomized, double-masked, sham-controlled studies.

All participants had been treated with pegcetacoplan, 15 mg per 0.1-mL intravitreal injection, monthly or every other month, or sham injection monthly or every other month.

The primary end point was the least-squares mean change from baseline in area of retinal pigment epithelium (RPE) and outer retinal atrophy in each of the 3 treatment arms (pegcetacoplan monthly, pegcetacoplan every other month, and pooled sham [sham monthly and sham every other month]) at 24 months, Fu and associates explained.

Post hoc analysis findings

Among the 936 participants (mean age, 78.5 years; 60.9% women), the authors reported, “… pegcetacoplan but not sham treatment was associated with reduced growth rates of SD-OCT biomarkers for GA for up to 24 months. Reductions vs. sham in the least-squares mean change from the baseline values of RPE and outer retinal atrophy area were detectable at every time point from 3 through 24 months (least squares mean difference vs. pooled sham at month 24, pegcetacoplan monthly, −0.86 mm2; 95% confidence interval [CI], −1.15 to −0.57; P < 0.001; pegcetacoplan every other month, −0.69 mm2; 95% CI, −0.98 to −0.39; P < 0.001).

They also mentioned that this association was more pronounced with more frequent dosing (pegcetacoplan monthly vs. pegcetacoplan every other month at month 24, −0.17 mm2; 95% CI, −0.43 to 0.08; P = 0.17). Stronger associations were observed in the parafoveal and perifoveal regions for both pegcetacoplan monthly and pegcetacoplan every other month, the authors reported.

“These findings offer additional insight into the potential effects of pegcetacoplan on the development of GA, including potential effects on the retinal pigment epithelium and photoreceptors,” Fu and associates concluded.

References:
  1. Fu DJ, Bagga P, Naik G, et al. Pegcetacoplan treatment and consensus features of geographic atrophy over 24 months. JAMA Ophthalmol. Published online May 9, 2024. doi:10.1001/jamaophthalmol.2024.1269
  2. Arslan J, Samarasinghe G, Benke KK, et al. Artificial intelligence algorithms for analysis of geographic atrophy: a review and evaluation. Transl Vis Sci Technol. 2020;9:57. doi:10.1167/tvst.9.2.57
  3. Cleland SC, Konda SM, Danis RP, et al. Quantification of geographic atrophy using spectral domain OCT in age-related macular degeneration.Ophthalmol Retina. 2021;5:41-48. doi:10.1016/j.oret.2020.07.006
  4. Wu Z, Schmitz-Valckenberg S, Blodi BA, et al. Reticular pseudodrusen: interreader agreement of evaluation on OCT imaging in age-related macular degeneration.Ophthalmol Sci. 2023;3(4):100325. doi:10.1016/j.xops.2023.100325
Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.